Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010

Vaccine

Volumn 32, Issue 34, 2014, Pages 4356-4363

  Lamb, Karen E ^a,i   Flasche, Stefan ^a,j   Diggle, Mathew ^b   Inverarity, Donald ^c   Greenhalgh, David ^a   Jefferies, Johanna M ^d,k   Smith, Andrew ^f   Edwards, Giles F S ^e   Denham, Barbara ^e   McMenamin, Jim ^g   McDonald, Eisin ^g   Mitchell, Tim J ^h   Clarke, Stuart C ^d,j,k   Robertson, Chris ^a,g  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c MONKLANDS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e STOBHILL HOSPITAL   (United Kingdom)

^f GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^g HEALTH PROTECTION SCOTLAND   (United Kingdom)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j PUBLIC HEALTH ENGLAND   (United Kingdom)

^k UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Invasive pneumococcal disease; PCV7; Sequence type; Serotype

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; VACCINE;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CHILD; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTILOCUS SEQUENCE TYPING; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; ADOLESCENT; CLASSIFICATION; EPIDEMIOLOGY; HEALTH SURVEY; INFANT; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; SEROTYPING; STATISTICAL MODEL; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SCOTLAND; SEROGROUP; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84903820284     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.079     Document Type: Article

References (44)

1. World Health Organisation Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104.
2. Brueggemann A.B., Peto T.E., Crook D.W., Butler J.C., Kristinsson K.G., Spratt B.G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190:1203-1211.
3. George A.C., Melegaro A. Invasive pneumococcal infection in England and Wales 1999. Commun Dis Rep CDR Wkly 2001, 11:4-17.
4. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
5. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:468-472.
6. Albrich W.C., Baughman W., Schmotzer B., Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44:1569-1576.
7. Beall B., McEllistrem M.C., Gertz R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006, 44:999-1017.
8. Sharma D., Baughman W., Holst A., Thomas S., Jackson D., da Gloria Carvalho M., Beall B., Satola S., Jerris R., Jain S., Farley M.M., Nuorti J.P. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 2013, 32(2):e45-53.
9. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., Ramirez M. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008, 14:835-843. Portuguese Surveillance Group for the Study of Respiratory Pathogens.
10. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
11. Weinberger D.M., Trzcinski K., Lu Y.J., Bogaert D., Brandes A., Galagan J., et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathogens 2009, 5:e1000476.
12. Brueggemann A.B., Griffiths D.T., Meats E., Peto T., Crook D.W., Spratt B.G. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003, 187:1424-1432.
13. Brueggemann A.B., Pai R., Crook D.W., Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007, 3:e168.
14. Ansaldi F., Canepa P., de Florentiis D., Bandettini R., Durando P., Icardi G. Increasing incidence of Streptococcus pneumoniae serotype 19A and emergence of two vaccine escape recombinant ST695 strains in Liguria, Italy, 7 years after implementation of the 7-valent conjugated vaccine. Clin Vaccine Immunol 2011, 18:343-345.
15. Choi E.H., Kim S.H., Eun B.W., Kim S.J., Kim N.H., Lee J., et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008, 14:275-281.
16. Mahjoub-Messai F., Doit C., Koeck J.L., Billard T., Evrard B., Bidet P., et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 2009, 47:837-840.
17. Health Protection Scotland. Immunisation and Vaccine Preventable Diseases Weekly Report Articles, htt p://w ww.hps.scot.nhs.uk/immvax/wrdetail.aspx?id=54590&wrtype=9#images. (Last accessed 17.04.13).
18. Jefferies J.M., Smith A.J., Edwards G.F.S., McMenamin J., Mitchell T.J., Clarke S.C. Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol 2010, 48:1512.
19. Kirkham L.A., Jefferies J.M., Kerr A.R., Jing Y., Clarke S.C., Smith A., et al. Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol 2006, 44:151-159.
20. Smart L.E. Serotyping of Streptococcus pneumoniae strains by coagglutination. J Clin Pathol 1986, 39:328-331.
21. Clarke S.C., Diggle M.A. Automated PCR/sequence template purification. Mol Biotechnol 2002, 21:221-224.
22. Enright M.C., Spratt B.G. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 1998, 144(Pt 11):3049-3060.
23. Jefferies J., Clarke S.C., Diggle M.A., Smith A., Dowson C., Mitchell T. Automated pneumococcal MLST using liquid-handling robotics and a capillary DNA sequencer. Mol Biotechnol 2003, 24:303-308.
24. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995, 57:289-300.
25. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
26. Flasche S., Slack M., Miller E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Eurosurveillance 2011, 16:1-6.
27. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2005.
28. Donkor E.S. Molecular typing of the pneumococcus and its application in epidemiology in sub-Saharan Africa. Front Cell Infect Microbiol 2013, 3:12.
29. Farrell D.J., Felmingham D., Shackcloth J., Williams L., Maher K., Hope R., et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008, 62(Suppl. 2):ii87-ii95.
30. van der Linden M., Reinert R.R., Kern W.V., Imohl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis 2013, 13:70.
31. Liesenborghs L., Verhaegen J., Peetermans W., Vandeven J., Flamaing J. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine 2013, 31:1529-1534.
32. Leal J., Vanderkooi O., Church D., Macdonald J., Tyrrell G., Kellner J. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J 2012, 31:e169-e175.
33. Centers for Disease Control Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Surveill Summ 2005, 54:893-897.
34. Bettinger J.A., Scheifele D.W., Kellner J.D., Halperin S.A., Vaudry W., Law B., et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010, 28:2130-2136.
35. Lehmann D., Willis J., Moore H.C., Giele C., Murphy D., Keil A.D., et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010, 50:1477-1486.
36. Halasa N.B., Grijalva C.G., Arbogast P.G., Talbot T.R., Craig A.S., Griffin M.R., et al. Near complete elimination of the seven valent pneumococcal conjugate vaccine serotypes in Tennessee. Pediatr Infect Dis J 2013.
37. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
38. van Deursen A.M., van Mens S.P., Sanders E.A., Vlaminckx B.J., de Melker H.E., Schouls L.M., et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerging Infectious Diseases 2012, 18:1729-1737.
39. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008, 27:963-968.
40. Rodenburg G.D., de Greeff S.C., Jansen A.G.C.S., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16:816-823.
41. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116:e408-e413.
42. Flasche S., Van Hoek A.J., Sheasby E., Waight P., Andrews N., Sheppard C., et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011, 2011.
43. Bewick T., Sheppard C., Greenwood S., Slack M., Trotter C., George R., et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012, 67:540-545.
44. Kyaw M.H., Christie P., Clarke S.C., Mooney J.D., Ahmed S., Jones I.G., et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 2003, 37:1283-1291.